Médecine

Paramédical

Autres domaines


S'abonner

Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease : Running title: Propolis against SARS-CoV-2 infection and COVID-19 - 28/10/20

Doi : 10.1016/j.biopha.2020.110622 
Andresa Aparecida Berretta a , Marcelo Augusto Duarte Silveira b , José Manuel Cóndor Capcha c , David De Jong d,
a Research, Development and Innovation Department, Apis Flora Indl. Coml. Ltda, Ribeirão Preto, São Paulo, Brazil 
b D'Or Institute for Research and Education (IDOR), Hospital São Rafael, Salvador, Brazil 
c Interdisciplinary Stem Cell Institute at Miller School of Medicine, University of Miami, Miami, Florida, United States 
d Genetics Department, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Highlights

Propolis, made by bees from bioactive plant resins, has antiviral activity.
Propolis potentially can interfere with host cell invasion by SARS-CoV-2.
Propolis blocks proinflammatory PAK1, a kinase highly expressed in COVID19 patients.
Standardized propolis has consistent properties for lab and clinical research.
Propolis is a safe widely consumed functional food with medicinal properties.

Le texte complet de cet article est disponible en PDF.

Abstract

Propolis, a resinous material produced by honey bees from plant exudates, has long been used in traditional herbal medicine and is widely consumed as a health aid and immune system booster. The COVID-19 pandemic has renewed interest in propolis products worldwide; fortunately, various aspects of the SARS-CoV-2 infection mechanism are potential targets for propolis compounds. SARS-CoV-2 entry into host cells is characterized by viral spike protein interaction with cellular angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2. This mechanism involves PAK1 overexpression, which is a kinase that mediates coronavirus-induced lung inflammation, fibrosis, and immune system suppression. Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. In pre-clinical studies, propolis promoted immunoregulation of pro-inflammatory cytokines, including reduction in IL-6, IL-1 beta and TNF-α. This immunoregulation involves monocytes and macrophages, as well as Jak2/STAT3, NF-kB, and inflammasome pathways, reducing the risk of cytokine storm syndrome, a major mortality factor in advanced COVID-19 disease. Propolis has also shown promise as an aid in the treatment of various of the comorbidities that are particularly dangerous in COVID-19 patients, including respiratory diseases, hypertension, diabetes, and cancer. Standardized propolis products with consistent bioactive properties are now available. Given the current emergency caused by the COVID-19 pandemic and limited therapeutic options, propolis is presented as a promising and relevant therapeutic option that is safe, easy to administrate orally and is readily available as a natural supplement and functional food.

Le texte complet de cet article est disponible en PDF.

Keywords : Propolis, SARS-CoV-2, COVID-19, Antiviral, Anti-inflammatory, PAK1 blocker


Plan


© 2020  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131

Article 110622- novembre 2020 Retour au numéro
Article précédent Article précédent
  • Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents
  • Li Su, Ye Tu, De-pei Kong, Da-gui Chen, Chen-xi Zhang, Wan-nian Zhang, Chun-lin Zhuang, Zhi-bin Wang
| Article suivant Article suivant
  • Polymer-hybrid nanoparticles: Current advances in biomedical applications
  • Daniel Crístian Ferreira Soares, Stephanie Calazans Domingues, Daniel Bragança Viana, Marli Luiza Tebaldi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.